KEYNOTE-028

PMID: 28813164 (PD1/PDL1-157)

KEYNOTE-028

(PD1/PDL1-156)
(PD1/PDL1-157)

Primary Endpoint: ORR, safety & tolerability

Secondary Endpoint:PFS, OS, duration of response

Phase Ib multi cohort study(20 cohorts)

Entry n=163 → Evaluable PD-L1 n=145

↓

Positive PD-L1 n=46 (31.7%)

↓

n=24 Pembrolizumab
10mg/kg every 2weeks
24 months or until PD

SCLC or NEC
n=23 n=1

化学療法既治療
小細胞肺癌患者
進展型小細胞肺癌
・PD-L１発現
(TPS≧1%)

Type of prior therapy*	
Chemotherapy	24 (100)
Radiotherapy	1 (4.2)
Investigational tyrosine kinase inhibitor	1 (4.2)
Other investigational therapy	1 (4.2)
Prior chemotherapy type*†	
Cisplatin/carboplatin plus etoposide	24 (100)
Irinotecan or topotecan	11 (45.8)
Taxane	7 (29.2)
Lines of prior therapy‡	
1	3 (12.5)
2	12 (50.0)
≥ 3	9 (37.5)

median Time to response	median duration of response	ORR	Grade3-5AE
2.0ヶ月	19.4ヵ月	33.3%	2/24

historical response rates of 7% to 24% for topotecan

mPFS 1.9ヶ月
mOS 9.7ヶ月

1 patient ; CR
7 patients ; PR
1 patient ; SD
13 patient ; PD

asthenia (n = 7)
fatigue (n = 7)
cough (n = 6)

※本試験のORR33%であり、CM032でのORR10%であった。
CM032では、allcomerでもあり、PD-L1高発現がある程度有効な可能性を示唆している。

J Clin Oncol. 2017 Dec 1;35(34):3823-3829. doi: 10.1200/JCO.2017.72.5069. Epub 2017 Aug 16.

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.

Ott PA[1], Elez E[1], Hiret S[1], Kim DW[1], Morosky A[1], Saraf S[1], Piperdi B[1], Mehnert JM[1].



Table 1. Patient and Disease Characteristics at Baseline

Characteristic	No. (%) of Patients (n = 24)
Median age, years (range)	60.5 (41-80)
Sex	
Male	14 (58.3)
Female	10 (41.7)
Ethnicity	
White	13 (54.2)
Asian	3 (12.5)
Not specified	8 (33.3)
ECOG performance status	
0	7 (29.2)
1	17 (70.8)
Stable brain metastases	3 (12.5)
Histology	
Small-cell	23 (95.8)
Neuroendocrine	1 (4.2)
Type of prior therapy*	
Chemotherapy	24 (100)
Radiotherapy	1 (4.2)
Investigational tyrosine kinase inhibitor	1 (4.2)
Other investigational therapy	1 (4.2)
Prior chemotherapy type*†	
Cisplatin/carboplatin plus etoposide	24 (100)
Irinotecan or topotecan	11 (45.8)
Taxane	7 (29.2)
Lines of prior therapy‡	
1	3 (12.5)
2	12 (50.0)
≥ 3	9 (37.5)

Abbreviation: ECOG, Eastern Cooperative Oncology Group.
*Patients could have received ≥ 1 types of prior therapy.
†Not all prior therapies are listed.
‡Includes adjuvant and neoadjuvant therapies.

PMID: 28813164 (PD1/PDL1-157)

Table 2. Treatment-Related Adverse Events

Adverse Event and Grade	No. (%)
Any	16 (66.7)
Arthralgia	
1	3 (12.5)
2	1 (4.2)
Asthenia	
1	2 (8.3)
2	1 (4.2)
3	1 (4.2)
Rash*	4 (16.7)
Diarrhea*	3 (12.5)
Fatigue*	3 (12.5)
Dry skin*	2 (8.3)
Insomnia*	2 (8.3)
Excessive tearing*	2 (8.3)
Myalgia	
1	1 (4.2)
2	1 (4.2)
Nausea*	2 (8.3)

NOTE. Experienced by ≥ 5% of patients regardless of grade.
*Grade 1 only.

Table 3. Confirmed Efficacy Results (investigator-assessed) in the Total Population

Efficacy	Value of Patient Population (n = 24)
ORR*, No. (% [95% CI])	8 (33.3 [15.6-55.3])
CR, No. (%)	1 (4.2)
PR, No. (%)	7 (29.2)
SD, No. (%)	1 (4.2)
Median DOR, months† (range)	19.4 (≥ 3.6 to ≥ 20.0)
Median TTR, months (95% CI)	2.0 (1.7–3.7)
DCR‡, No. (% [95% CI])	8 (33.3 [15.6-55.3])
Progressive disease, No. (%)	13 (54.2)
Not evaluable, No. (%)	2 (8.3)
PFS	
Events, No. (%)	20 (83.3)
Median, months (95% CI)	1.9 (1.7-5.9)
Six-month rate, % (95% CI)	28.6 (12.4-47.2)
Twelve-month rate, % (95% CI)	23.8 (9.1-42.3)
OS	
Events, No. (%)	15 (62.5)
Median, months (95% CI)	9.7 (4.1-NR)
Six-month rate, % (95% CI)	66.0 (43.3-81.3)
Twelve-month rate, % (95% CI)	37.7 (18.4-57.0)

KEYNOTE-028 (PD1/PDL1-157)





KEYNOTE-028 (PD1/PDL1-157)